Machine Learning Screening for Disulfidptosis Genes-Associated Immunosuppression Status in Osteosarcoma and Rhabdomyosarcoma DOI

RuiZong Wang,

J. Zhang, Kai Zhong

et al.

Published: Jan. 1, 2023

The discovery of Disulfidptosis as a novel form cell death has provided new insights for the treatment cancer and various diseases. Osteosarcoma rhabdomyosarcoma are malignant sarcomas that predominantly affect children, but molecular mechanisms underlying development these diseases remain unclear. Therefore, our study aimed to investigate involvement in both osteosarcoma rhabdomyosarcoma. To accomplish this, we analyzed bulk RNA transcriptome sequencing data obtained from Gene Expression Omnibus (GEO) datasets Therapeutically Applicable Research Generate Effective Treatments (TARGET) databases. By employing non-negative matrix factorization (NMF), successfully identified an immunosuppressive subtype based on genes associated with Disulfidptosis. Notably, this exhibited poor immune infiltration. Furthermore, employed combination 100 machine learning algorithms identify five most representative related Disulfidptosis: ACTN4, MYH9, FLNA, MYH10, IQGAP1. These played crucial role characterizing subtypes determining patient's risk score. Particularly, IQGAP1 independent prognostic effects showed promise potential therapeutic target marker. Additionally, findings suggested strong association between macrophages Disulfidptosis, which may further impact prognosis patients osteosarcoma.

Language: Английский

Natural and Bioengineered Extracellular Vesicles in Diagnosis, Monitoring and Treatment of Cancer DOI
Xin Luo, Kathleen M. McAndrews, Raghu Kalluri

et al.

ACS Nano, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 27, 2025

Extracellular vesicles (EVs) are cell derived nanovesicles which implicated in both physiological and pathological intercellular communication, including the initiation, progression, metastasis of cancer. The exchange biomolecules between stromal cells cancer via EVs can provide a window to monitor development real time for better diagnostic interventional strategies. In addition, process secretion internalization by tumor microenvironment (TME) be exploited delivering therapeutics. have potential targeted, biocompatible, efficient delivery platform treatment other diseases. Natural as well engineered nanomedicine immense disease intervention. Here, we an overview current knowledge EVs' function therapeutic applications setting, EV engineering

Language: Английский

Citations

3
Biological impact and therapeutic implication of tumor-associated macrophages in hepatocellular carcinoma DOI Creative Commons
Deming Li, Ting Zhang, Ye Guo

et al.

Cell Death and Disease, Journal Year: 2024, Volume and Issue: 15(7)

Published: July 12, 2024

The tumor microenvironment is a complex space comprised of normal, cancer and immune cells. macrophages are considered as the most abundant cells in their function tumorigenesis interesting. Macrophages can be present M1 M2 polarization that show anti-cancer oncogenic activities, respectively. Tumor-associated (TAMs) mainly have they increase due to secretion factors, cytokines affecting molecular pathways. Hepatocellular carcinoma (HCC) among predominant tumors liver spite understanding its pathogenesis, role progression still requires more attention. presence TAMs HCC causes an growth invasion one reasons induction glycolysis such metabolic reprogramming makes distinct from normal promotes malignancy. Since stimulates HCC, networks regulating conversion been highlighted moreover, drugs compounds with ability targeting suppressing phenotypes or at least activity utilized. aggressive behavior biological functions result development therapy resistance. provide cell-cell communication by secreting exosomes having various types biomolecules transfer change activity. Finally, non-coding RNA transcripts affect HCC.

Language: Английский

Citations

12
Genomic Variants and Worldwide Epidemiology of Breast Cancer: A Genome-Wide Association Studies Correlation Analysis DOI Open Access
Giovanna Gilioli da Costa Nunes, Lilian Marques de Freitas, Natasha Monte

et al.

Genes, Journal Year: 2024, Volume and Issue: 15(2), P. 145 - 145

Published: Jan. 23, 2024

Breast cancer (BCa) is the most common and leading cause of death among women globally. This can be explained by genetic factor this disease. article aims to correlate epidemiological data, worldwide incidence, mortality BCa with Single-Nucleotide Polymorphisms (SNPs) associated susceptibility severity in different populations. Two hundred forty variants susceptibility/severity were selected from literature through Genome-Wide Association Studies (GWAS). The allele frequencies obtained 1000 Genomes Project, data World Health Organization (WHO). rates, evaluated using Pearson’s correlation. Our study demonstrated that 11 SNPs (rs3817578, rs4843437, rs3754934, rs61764370, rs780092, rs2290203, rs10411161, rs6001930, rs16886165, rs8051542 rs4973768) significantly correlated ethnic groups. Seven polymorphisms rs6001930 rs16886165) inversely incidence rate four (rs4843437, directly rate. African South-East Asian populations have a lower risk developing when terms factors since they possess characterized as protective, their higher frequency cases. investigated here are likely predispose individuals BCa. described promising for implementing personalized strategies screen breast diverse

Language: Английский

Citations

10
The current status and future of PD-L1 in liver cancer DOI Creative Commons
Liyuan Hao, Shenghao Li, Jiali Deng

et al.

Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 14

Published: Dec. 12, 2023

The application of immunotherapy in tumor, especially immune checkpoint inhibitors (ICIs), has played an important role the treatment advanced unresectable liver cancer. However, efficacy ICIs varies greatly among different patients, which aroused people’s attention to regulatory mechanism programmed death ligand-1 (PD-L1) escape PD-L1 is regulated by multiple levels and signaling pathways hepatocellular carcinoma (HCC), including gene variation, epigenetic inheritance, transcriptional regulation, post-transcriptional post-translational modification. More studies have also found that high expression may be main factor affecting what difference expressed types cells microenvironment HCC, type determines effect tumor remains unclear. Therefore, clarifying cancer can provide more basis for combined strategy. In addition its well-known plays a regulating cell proliferation promoting drug resistance cells, will reviewed this paper. addition, we summarized natural products drugs HCC.

Language: Английский

Citations

14
Do proton pump inhibitors affect the effectiveness of cyclin-dependent kinase 4/6 inhibitors in advanced HR positive, HER2 negative breast cancer? A meta-analysis DOI Creative Commons
Francisco Cézar Aquino de Moraes,

Caroline R. M. Pereira,

Vitor Kendi Tsuchiya Sano

et al.

Frontiers in Pharmacology, Journal Year: 2024, Volume and Issue: 15

Published: May 6, 2024

Graphical Abstract

Language: Английский

Citations

6
Macrophage-derived extracellular vesicles as new players in chronic non-communicable diseases DOI Creative Commons

Fengjuan Lin,

Huiyu Luo,

Jiexian Wang

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 15

Published: Jan. 17, 2025

Macrophages are innate immune cells present in all tissues and play an important role almost aspects of the biology living organisms. Extracellular vesicles (EVs) released by transport their contents (micro RNAs, mRNA, proteins, long noncoding RNAs) to nearby or distant for cell-to-cell communication. Numerous studies have shown that macrophage-derived extracellular (M-EVs) a variety diseases show great potential as biomarkers, therapeutics, drug delivery vehicles diseases. This article reviews biological functions mechanisms M-EVs chronic non-communicable such cardiovascular diseases, metabolic cancer, inflammatory bone-related In addition, application systems various been summarized.

Language: Английский

Citations

0
Prospect of extracellular vesicles in tumor immunotherapy DOI Creative Commons

Wenbo Xia,

Yunhan Tan,

Y.-P. Liu

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: Feb. 26, 2025

Extracellular vesicles (EVs), as cell-derived small vesicles, facilitate intercellular communication within the tumor microenvironment (TME) by transporting biomolecules. EVs from different sources have varied contents, demonstrating differentiated functions that can either promote or inhibit cancer progression. Thus, regulating formation, secretion, and intake of becomes a new strategy for intervention. Advancements in EV isolation techniques spurred interest EV-based therapies, particularly immunotherapy. This review explores multifaceted various immunotherapy, highlighting their potential vaccines adoptive cell therapy. Furthermore, we explore nanoparticle delivery systems Finally, discuss current state clinical settings future directions, aiming to provide crucial information advance development application treatment.

Language: Английский

Citations

0
Sophisticated roles of tumor microenvironment in resistance to immune checkpoint blockade therapy in hepatocellular carcinoma DOI Open Access
Yizhe Zhang, Yunshu Ma,

Ensi Ma

et al.

Cancer Drug Resistance, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 26, 2025

Hepatocellular carcinoma (HCC) remains a serious threat to global health, with rising incidence and mortality rates. Therapeutic options for advanced HCC are quite limited, the overall prognosis poor. Recent advancements in immunotherapy, particularly immune-checkpoint blockade (ICB) targeting anti-PD1/PD-L1 anti-CTLA4, have facilitated paradigm shift cancer treatment, demonstrating substantial survival benefits across various types, including HCC. However, only subset of patients exhibit favorable response ICB therapy, its efficacy is often hindered by development resistance. There many studies explore underlying mechanisms response. In this review, we compiled latest progression immunotherapies systematically summarized sophisticated which components tumor microenvironment (TME) regulate resistance therapy. Additionally, also outlined some scientific rationale strategies boost antitumor immunity enhance These insights may serve as roadmap future research help improve outcomes patients.

Language: Английский

Citations

0
Epigenetic regulators combined with tumour immunotherapy: current status and perspectives DOI Creative Commons
Huan Zhang, Yuepeng Pang, Ling Yi

et al.

Clinical Epigenetics, Journal Year: 2025, Volume and Issue: 17(1)

Published: March 21, 2025

Immunotherapy, particularly immune checkpoint inhibitor therapy, has demonstrated clinical benefits in solid tumours. Despite its satisfactory efficacy, it still faces several issues, such as limited eligibility, low response rates and cytotoxicity. Cancer epigenetics implies that tumour cells exhibit unique phenotypes because of their characteristics, thus reprogramming the epigenome holds promise for cancer therapy. Epigenetic regulation plays an important role regulating gene expression during development maintenance. regulators induce cell cycle arrest, apoptosis differentiation cells, thereby exerting anti-tumour effects. Recent studies have revealed a significant correlation between epigenetic regulatory factors Epigenetics can modulate various aspects microenvironment to enhance sensitivity immunotherapy, lowering concentration required mitigating This review primarily discusses DNA methyltransferase inhibitors, histone deacetylase enhancer zeste homolog 2 inhibitors lysine-specific demethylase 1 which are associated with transcriptional repression. repression alters genes involved checkpoint, enhancing effectiveness immunotherapy. We also discuss potential challenges immunotherapy highlight advantages, application research on integrating

Language: Английский

Citations

0
Cycloastragenol Inhibits Colorectal Cancer Metastasis by Attenuating the Activation of Pro-Tumor Macrophages Via Extracellular Vesicles-Mediated Glutamine-Γ-Aminobutyric Acid Metabolism DOI

Jing Zhou,

Ling Li,

Yunzhou Pu

et al.

Published: Jan. 1, 2025

Language: Английский

Citations

0